{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T18:03:53Z","timestamp":1793556233122,"version":"4.5.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>As a key signaling molecule network in the tumor immune microenvironment, cytokines mediate intercellular communication through mechanisms such as autocrine and paracrine, exhibiting a significant \u201cdouble-edged sword\u201d effect during tumor initiation and progression. The dynamic regulation of this dual effect is influenced by the dependence on concentration, the variability within the tumor immune microenvironment, and the stages of tumor progression, ultimately representing the prolonged co-evolutionary result between tumors and the immune system. Cytokines, as a vital element of the immune microenvironment within tumors, influence cancer promotion by creating intricate networks. Therefore, disrupting this balance to alter the tumor growth environment is of great significance for achieving tumor suppression. In terms of clinical translation, the combined strategy of cytokine therapy and immune checkpoint blockade therapy has significantly improved treatment efficacy by synergistically enhancing immune activation and relieving immune suppression. Meanwhile, approaches such as monoclonal antibodies and bispecific molecules targeting pro-tumor cytokines have provided new insights for overcoming therapeutic resistance. In-depth clarification of the molecular mechanisms underlying the dual effects of cytokines, and breaking through the limitations of single targets from a network perspective, will provide a new paradigm for cancer immunotherapy from basic mechanisms to clinical applications. This will promote the upgrading of targeting strategies towards \u201cdynamic regulation and synergistic intervention,\u201d ultimately improving the prognosis of cancer patients.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1701405","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:36:35Z","timestamp":1763534195000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["The \u201cdouble-edged sword\u201d effect of cytokines in cancer: coexisting opportunities and challenges"],"prefix":"10.3389","volume":"16","author":[{"given":"Xuan","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangzheqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/AIA.0b013e318034194e","article-title":"Cytokines, inflammation, and pain","volume":"45","author":"Zhang","year":"2007","journal-title":"Int Anesthesiol Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.11817\/j.issn.1672-7347.2023.230231","article-title":"Inflammation and tumor microenvironment","volume":"48","author":"Niu","year":"2023","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2024.11.011","article-title":"Cytokines in cancer","volume":"43","author":"Kureshi","year":"2025","journal-title":"Cancer Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03271-5","article-title":"Cytokine-mediated CAR T therapy resistance in AML","volume":"30","author":"Bhagwat","year":"2024","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a028472","article-title":"Cytokines in cancer immunotherapy","volume":"10","author":"Waldmann","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.028","article-title":"The \u03b3(c) family of cytokines: basic biology to therapeutic ramifications","volume":"50","author":"Leonard","year":"2019","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.153.4.1697","article-title":"Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production","volume":"153","author":"Nastala","year":"1994","journal-title":"J Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13045-022-01349-6","article-title":"TGF-\u03b2 signaling in the tumor metabolic microenvironment and targeted therapies","volume":"15","author":"Shi","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03293-4","article-title":"The complex roles of IL-36 and IL-38 in cancer: friends or foes","volume":"44","author":"Finucane","year":"2025","journal-title":"Oncogene"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501217","article-title":"Costimulation endows immunotherapeutic CD8 T cells with IL-36 responsiveness during aerobic glycolysis","volume":"196","author":"Tsurutani","year":"2016","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2020.06.006","article-title":"IL-36 in chronic inflammation and cancer","volume":"55","author":"Neurath","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-016-5098-7","article-title":"Role of interleukin-6 in cancer progression and therapeutic resistance","volume":"37","author":"Kumari","year":"2016","journal-title":"Tumour Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2013.1761","article-title":"Role of IL-9 and STATs in hematological Malignancies (Review)","volume":"7","author":"Chen","year":"2014","journal-title":"Oncol Lett"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mucimm.2024.10.003","article-title":"A reappraisal of IL-9 in inflammation and cancer","volume":"18","author":"Bick","year":"2025","journal-title":"Mucosal Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859738","article-title":"IL-9 producing tumor-infiltrating lymphocytes and treg subsets drive immune escape of tumor cells in non-small cell lung cancer","volume":"13","author":"Heim","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1038\/s41467-022-31596-7","article-title":"Mouse pulmonary interstitial macrophages mediate the pro-tumorigenic effects of IL-9","volume":"13","author":"Fu","year":"2022","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.82317","article-title":"CXCL12-CXCR4\/CXCR7 axis in cancer: from mechanisms to clinical applications","volume":"19","author":"Yang","year":"2023","journal-title":"Int J Biol Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20190418","article-title":"Biology and therapeutic potential of interleukin-10","volume":"217","author":"Saraiva","year":"2020","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2025.10.002","article-title":"Dual effects and balanced regulation of cytokines in sepsis","author":"Wang","year":"2025","journal-title":"Trends Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cytogfr.2005.09.006","article-title":"TGF-beta and cancer","volume":"17","author":"Bierie","year":"2006","journal-title":"Cytokine Growth Factor Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1172\/jci18899","article-title":"TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression","volume":"112","author":"Tang","year":"2003","journal-title":"J Clin Invest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s1286-4579(99)00251-8","article-title":"TGF-beta and cancer","volume":"1","author":"Reiss","year":"1999","journal-title":"Microbes Infect"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a022277","article-title":"TGF-\u03b2 Family signaling in tumor suppression and cancer progression","volume":"9","author":"Seoane","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2628","article-title":"Tumour necrosis factor and cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7150\/jca.53349","article-title":"The Expression of Transcription Factors is Different in Papillary Thyroid Cancer Cells during TNF - \u03b1 induced EMT","volume":"12","author":"Lv","year":"2021","journal-title":"J Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers3032811","article-title":"Tumor necrosis factor (TNF) and chemokines in colitis-associated cancer","volume":"3","author":"Mukaida","year":"2011","journal-title":"Cancers (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2174\/1874467217666230908111754","article-title":"At the crossroads of TNF\u03b1 Signaling and cancer","volume":"17","author":"Manohar","year":"2024","journal-title":"Curr Mol Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.901277","article-title":"GM-CSF: A double-edged sword in cancer immunotherapy","volume":"13","author":"Kumar","year":"2022","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-13-2774","article-title":"GM-CSF production by tumor cells is associated with improved survival in colorectal cancer","volume":"20","author":"Nebiker","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.22.4931","article-title":"Rapid clinical deterioration and leukemoid reaction after treatment of urothelial carcinoma of the bladder: possible effect of granulocyte colony-stimulating factor","volume":"27","author":"Perez","year":"2009","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1158\/0008-5472.Can-12-0806","article-title":"Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors","volume":"73","author":"Urdinguio","year":"2013","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028480","article-title":"Interferon \u03b3 and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity","volume":"11","author":"Alspach","year":"2019","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12943-025-02294-x","article-title":"Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors","volume":"24","author":"Wawrzyniak","year":"2025","journal-title":"Mol Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/s12276-024-01301-3","article-title":"Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends","volume":"56","author":"Im","year":"2024","journal-title":"Exp Mol Med."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1433989","article-title":"IL-2 based cancer immunotherapies: an evolving paradigm","volume":"15","author":"Rokade","year":"2024","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007530","article-title":"New perspectives in cancer immunotherapy: targeting IL-6 cytokine family","volume":"11","author":"Soler","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-011-8262-6","article-title":"Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy","volume":"51","author":"Sato","year":"2011","journal-title":"Immunol Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1161067","article-title":"The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions","volume":"14","author":"Carlini","year":"2023","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/cco.0000000000000006","article-title":"Current status of interleukin-10 and regulatory T-cells in cancer","volume":"25","author":"Dennis","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cimb46100686","article-title":"Interleukin-12 delivery strategies and advances in tumor immunotherapy","volume":"46","author":"Dong","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1103149","article-title":"Tumor-associated macrophage polarization in the inflammatory tumor microenvironment","volume":"13","author":"Zou","year":"2023","journal-title":"Front Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030564","article-title":"Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy","volume":"13","author":"Mercogliano","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc1252","article-title":"Cytokines in cancer pathogenesis and cancer therapy","volume":"4","author":"Dranoff","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-100-5-671","article-title":"Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome","volume":"100","author":"Groopman","year":"1984","journal-title":"Ann Intern Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/jco.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1986.4.6.900","article-title":"Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients","volume":"4","author":"Golomb","year":"1986","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199311253292203","article-title":"Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte","volume":"329","author":"Solal-Celigny","year":"1993","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2024.04.006","article-title":"Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities","volume":"45","author":"Konen","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-3266-5_9","article-title":"Functions of immune checkpoint molecules beyond immune evasion","volume":"1248","author":"Zhang","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00075-5","article-title":"Radiotherapy, immunity, and immune checkpoint inhibitors","volume":"25","author":"Lynch","year":"2024","journal-title":"Lancet Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/s1470-2045(23)00524-7","article-title":"Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials","volume":"25","author":"Fujiwara","year":"2024","journal-title":"Lancet Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.872010","article-title":"Cytokine based immunotherapy for cancer and lymphoma: biology, challenges and future perspectives","volume":"13","author":"Atallah-Yunes","year":"2022","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B64","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","article-title":"Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04596-3","article-title":"Efficacy and safety of interferon-alpha 1b combined with PD-1 monoclonal antibody in patients with unresectable stage IV melanoma: a retrospective study","volume":"149","author":"Zhu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adv9161","article-title":"Combination LIGHT overexpression and checkpoint blockade disrupts the tumor immune environment impacting colorectal liver metastases","volume":"11","author":"Keenan","year":"2025","journal-title":"Sci Adv"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1196970","article-title":"Bispecific antibody targeting TGF-\u03b2 and PD-L1 for synergistic cancer immunotherapy","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-3-319-53156-4_2","article-title":"Interleukin-2: old and new approaches to enhance immune-therapeutic efficacy","volume":"995","author":"Dhupkar","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15110","article-title":"Cytokine-based cancer immunotherapy: challenges and opportunities for IL-10","volume":"41","author":"Rallis","year":"2021","journal-title":"Anticancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1701405\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:36:37Z","timestamp":1763534197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1701405\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":69,"alternative-id":["10.3389\/fimmu.2025.1701405"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1701405","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"article-number":"1701405"}}